| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A reexamination using data from the U.S. and Australia |
0 |
0 |
0 |
15 |
1 |
4 |
4 |
134 |
| Benefits and Costs of Newer Drugs: An Update |
0 |
0 |
1 |
261 |
3 |
3 |
6 |
651 |
| CONTRIBUTIONS TO FEDERAL ELECTION CAMPAIGNS BY GOVERNMENT CONTRACTORS |
0 |
0 |
0 |
1 |
1 |
1 |
1 |
894 |
| CROWDING OUT: THE IMPACT OF THE STRATEGIC DEFENSE INITIATIVE ON U.S. CIVILIAN R&D INVESTMENT AND INDUSTRIAL COMPETITIVENESS |
0 |
0 |
0 |
0 |
1 |
2 |
2 |
895 |
| Computer Use and Productivity Growth in Federal Government Agencies, 1987 to 1992 |
0 |
0 |
0 |
190 |
2 |
2 |
3 |
1,420 |
| Computer Use and Productivity Growth in federal Government Agencies |
0 |
0 |
0 |
0 |
2 |
4 |
5 |
1,415 |
| Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act |
0 |
0 |
0 |
152 |
1 |
4 |
6 |
780 |
| Does foreign direct investment transfer technology across borders? |
0 |
0 |
0 |
0 |
1 |
5 |
11 |
570 |
| Errors of Measurement in Output Deflators |
0 |
0 |
0 |
49 |
1 |
1 |
1 |
235 |
| GOVERNMENT SUBSIDIES TO PRIVATE MILITARY R&D INVESTMEN: DOD'S IR&D POLICY |
0 |
0 |
0 |
1 |
1 |
1 |
3 |
720 |
| Government Subsidies to Private Military R&D Investment: DOD's IR&D Policy |
0 |
0 |
0 |
115 |
1 |
2 |
3 |
593 |
| HOW ELASTIC IS THE GOVERNMENT'S DEMAND FOR WEAPONS? |
0 |
0 |
0 |
0 |
2 |
2 |
3 |
387 |
| Has medical innovation reduced cancer mortality? |
0 |
0 |
0 |
67 |
2 |
2 |
6 |
237 |
| Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003 |
0 |
0 |
1 |
41 |
0 |
3 |
4 |
202 |
| How Elastic is the Government's Demand for Weapons? |
0 |
0 |
0 |
27 |
4 |
7 |
8 |
234 |
| How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013 |
0 |
0 |
0 |
53 |
2 |
3 |
6 |
68 |
| IR&D Project Data and Theories of R&D Investment |
0 |
0 |
0 |
76 |
1 |
1 |
2 |
385 |
| Impact of Specialization on Health Outcomes – Evidence from U.S. Cancer Data |
0 |
0 |
0 |
47 |
0 |
2 |
4 |
183 |
| Importation and Innovation |
0 |
0 |
0 |
58 |
0 |
0 |
1 |
314 |
| Industrial De-Diversification and Its Consequences for Productivity |
0 |
0 |
0 |
7 |
3 |
3 |
5 |
67 |
| Industrial De-Diversification and its Consequences for Productivity |
0 |
0 |
0 |
68 |
3 |
5 |
6 |
304 |
| International R&D Spillovers: A Re-Examination |
0 |
0 |
1 |
448 |
4 |
5 |
8 |
1,199 |
| International R&D spillovers comment |
0 |
0 |
0 |
10 |
2 |
5 |
7 |
218 |
| Labor Market Institutions, Liquidity Constraints, and Macroeconomic Stability |
0 |
0 |
0 |
20 |
0 |
0 |
1 |
141 |
| Listen to your Doctor, or else!: Medication Under-use and Overuse and Long-term Health Outcomes of Danish Diabetes Patients |
0 |
0 |
0 |
23 |
5 |
7 |
10 |
78 |
| Ownership Structure and Corporate Performance in Japan |
0 |
0 |
0 |
228 |
3 |
3 |
6 |
739 |
| Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009 |
0 |
0 |
0 |
99 |
4 |
6 |
10 |
237 |
| Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010 |
0 |
0 |
0 |
23 |
0 |
1 |
2 |
150 |
| Pharmaceutical Innovation, Mortality Reduction, and Economic Growth |
0 |
0 |
1 |
376 |
1 |
2 |
6 |
1,639 |
| Pharmaceutical innovation and the longevity of Australians: a first look |
0 |
0 |
0 |
55 |
1 |
2 |
3 |
215 |
| Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "equipment for your health" |
0 |
0 |
0 |
217 |
2 |
4 |
5 |
902 |
| Private Investment in R&D to Signal Ability to Perform Government Contracts |
0 |
0 |
0 |
19 |
2 |
2 |
2 |
151 |
| R and D and Productivity at the Industry Level: Is There Still a Relationship? |
0 |
0 |
0 |
251 |
3 |
4 |
4 |
638 |
| R&D Investment and International Productivity Differences |
0 |
0 |
1 |
448 |
7 |
11 |
22 |
1,267 |
| Response to Baker and Fugh-Berman's Critique of my Paper, "Why has Longevity Increased more in some States than in others?" |
0 |
0 |
0 |
14 |
0 |
1 |
4 |
123 |
| Sources of U.S. Longevity Increase, 1960 -1997 |
0 |
0 |
0 |
59 |
0 |
1 |
4 |
614 |
| Sources of U.S. Longevity Increase, 1960-1997 |
0 |
0 |
0 |
183 |
3 |
5 |
6 |
986 |
| Spurious correlation in estimation of the health production function: A note |
0 |
1 |
1 |
91 |
2 |
11 |
15 |
443 |
| THE EFFECT OF TAKEOVERS ON THE EMPLOYMENT AND WAGES OF CENTRAL-OFFICE AND OTHER PERSONNEL |
0 |
0 |
0 |
1 |
2 |
2 |
3 |
442 |
| Technical Change, Learning, and Wages |
0 |
0 |
0 |
37 |
2 |
4 |
6 |
182 |
| The Allocation of Publicly-Funded Biomedical Research |
0 |
0 |
0 |
68 |
1 |
4 |
4 |
1,029 |
| The Allocation of Publicly-Funded Biomedical Research |
0 |
0 |
0 |
47 |
1 |
2 |
2 |
498 |
| The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey |
0 |
0 |
0 |
181 |
3 |
4 |
5 |
715 |
| The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey |
0 |
0 |
0 |
61 |
5 |
6 |
8 |
408 |
| The Comparative Advantage of Educated Workers in Implementing New Technology: Some Empirical Evidence |
0 |
0 |
0 |
116 |
5 |
8 |
11 |
490 |
| The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France |
0 |
0 |
0 |
59 |
2 |
4 |
4 |
234 |
| The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry |
0 |
0 |
0 |
283 |
0 |
1 |
1 |
948 |
| The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in The US Pharmaceuticals Industry |
0 |
0 |
0 |
0 |
3 |
4 |
5 |
9 |
| The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US |
0 |
0 |
1 |
38 |
0 |
0 |
1 |
136 |
| The Effect Of Takeovers On The Employment And Wages Of Central-Office And Other Personnel |
0 |
0 |
0 |
358 |
2 |
4 |
7 |
1,334 |
| The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output |
0 |
0 |
2 |
65 |
1 |
2 |
6 |
358 |
| The Effect of Drug Vintage on Survival: Micro Evidence from Puerto Rico's Medicaid Program |
0 |
0 |
0 |
45 |
1 |
1 |
2 |
388 |
| The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs |
1 |
1 |
2 |
138 |
2 |
8 |
11 |
904 |
| The Effect of New Drugs on Mortality from Rare Diseases and HIV |
0 |
0 |
0 |
82 |
1 |
1 |
1 |
600 |
| The Effect of New Political Administration on Federal Government Productivity and Employment |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
444 |
| The Effect of New Political Administration on Federal Government Productivity and Employment |
0 |
0 |
0 |
116 |
0 |
3 |
7 |
1,067 |
| The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files |
0 |
0 |
0 |
48 |
3 |
4 |
4 |
106 |
| The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey |
0 |
0 |
1 |
27 |
1 |
3 |
5 |
79 |
| The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality |
0 |
0 |
0 |
157 |
1 |
1 |
7 |
576 |
| The Effect of Takeovers on the Employment and Wages of Central-Office and Other Personnel |
0 |
0 |
0 |
197 |
3 |
5 |
6 |
496 |
| The Effects Of Leveraged Buyouts On Productivity And Related Aspects Of Firm Behavior |
0 |
1 |
1 |
1,037 |
3 |
6 |
8 |
2,509 |
| The Effects of Leveraged Buyouts on Productivity and Related Aspects of Firm Behavior |
0 |
0 |
0 |
519 |
1 |
7 |
8 |
1,328 |
| The Effects of Mergers on Prices, Costs, And Capacity Utilization in the U.S. Air Transportation Industry, 1970-84 |
0 |
0 |
0 |
11 |
2 |
2 |
4 |
47 |
| The Effects of Mergers on Prices, Costs, and Capacity Utilization in the U.S. Air Transportation Industry, 1970-84 |
0 |
0 |
0 |
62 |
1 |
1 |
2 |
345 |
| The Effects of Off-label Drug Use on Disability and Medical Expenditure |
0 |
0 |
0 |
9 |
3 |
4 |
6 |
19 |
| The European Strategic Program for Research in Information Technologie (ESPRIT): An Ex-Post Analysis |
0 |
0 |
0 |
0 |
2 |
8 |
18 |
1,139 |
| The Expanding Pharmaceutical Arsenal in the War on Cancer |
0 |
0 |
0 |
113 |
1 |
2 |
2 |
407 |
| The Impact and Organization of Publicly-Funded Research and Development in the European Community |
0 |
0 |
0 |
117 |
1 |
2 |
3 |
894 |
| The Impact of Biomedical Knowledge Accumulation on Mortality: A Bibliometric Analysis of Cancer Data |
0 |
0 |
0 |
2 |
1 |
2 |
3 |
50 |
| The Impact of Hospital Quality-Related Practices on Health Outcomes |
0 |
0 |
0 |
48 |
0 |
1 |
2 |
244 |
| The Impact of Increased Utilization of HIV Drugs on Longevity and Medical Expenditures: An Assessment Based on Aggregate U.S. Time-Series Data |
0 |
0 |
1 |
49 |
1 |
2 |
4 |
368 |
| The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries |
0 |
0 |
0 |
13 |
3 |
4 |
6 |
49 |
| The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries |
0 |
0 |
0 |
3 |
1 |
3 |
4 |
37 |
| The Impact of New Laboratory Procedures and Other Medical Innovations on the Health of Americans, 1990-2003: Evidence from Longitudinal, Disease-Level Data |
0 |
0 |
1 |
36 |
3 |
4 |
5 |
275 |
| The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data |
0 |
0 |
0 |
25 |
0 |
2 |
3 |
118 |
| The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011 |
0 |
0 |
0 |
37 |
2 |
3 |
5 |
65 |
| The Impact of Public and Private Research Support on Premature Cancer Mortality and Hospitalization in the U.S., 1999-2013 |
0 |
0 |
0 |
34 |
1 |
2 |
7 |
46 |
| The Impact of R&D Investment On Productivity - New Evidence Using Linked R&D-LRD Data |
0 |
1 |
2 |
494 |
1 |
5 |
13 |
996 |
| The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence |
0 |
0 |
0 |
9 |
0 |
0 |
3 |
88 |
| The Impact of Therapeutic Procedure Innovation on Hospital Patient Longevity: Evidence from Western Australia, 2000-2007 |
0 |
0 |
1 |
17 |
0 |
1 |
3 |
91 |
| The Long-run Impact of New Medical Ideas on Cancer Survival and Mortality |
0 |
0 |
0 |
33 |
3 |
5 |
7 |
48 |
| The Output Contributions of Computer Equipment and Personnel: A Firm- Level Analysis |
0 |
0 |
0 |
195 |
1 |
3 |
7 |
789 |
| The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth |
0 |
0 |
0 |
187 |
0 |
3 |
7 |
696 |
| The effects of off-label drug use on disability and medical expenditure |
0 |
0 |
0 |
2 |
1 |
1 |
2 |
11 |
| The expanding pharmaceutical arsenal in the war on cancer |
0 |
0 |
0 |
119 |
2 |
2 |
2 |
538 |
| The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis |
0 |
0 |
1 |
27 |
4 |
7 |
9 |
84 |
| The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001 |
0 |
0 |
0 |
203 |
5 |
7 |
8 |
615 |
| Training, Tenure, and Productivity |
0 |
0 |
0 |
61 |
1 |
2 |
4 |
244 |
| USING LINKED CENSUS R&D-LRD DATA TO ANALYZE THE EFFECT OF R&D INVESTMENT ON TOTAL FACTOR PRODUCTIVITY GROWTH |
0 |
0 |
0 |
379 |
0 |
0 |
2 |
881 |
| Using Patents Data to Map Technical Change in Health-Related Areas |
0 |
0 |
0 |
97 |
0 |
2 |
7 |
272 |
| Total Working Papers |
1 |
4 |
19 |
9,855 |
154 |
291 |
476 |
45,164 |
| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia |
0 |
0 |
0 |
18 |
2 |
4 |
10 |
190 |
| Are drug prices subject to creative destruction? Evidence from the US, 1997–2017 |
0 |
0 |
1 |
9 |
0 |
1 |
4 |
22 |
| Are patients more adherent to newer drugs? |
0 |
0 |
0 |
1 |
0 |
0 |
4 |
27 |
| Are the More Educated More Likely to Use New Drugs? |
0 |
1 |
3 |
22 |
0 |
3 |
10 |
79 |
| Benefits and costs of newer drugs: an update |
0 |
0 |
1 |
88 |
2 |
2 |
5 |
429 |
| Book Reviews |
0 |
0 |
0 |
3 |
1 |
1 |
1 |
19 |
| Changing market opportunities and the structure of R & D investment: The case of energy |
0 |
0 |
0 |
10 |
0 |
0 |
1 |
65 |
| Computer Use and Productivity Growth in US Federal Government Agencies, 1987–92 |
0 |
0 |
0 |
1 |
2 |
3 |
5 |
14 |
| Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001–7 |
0 |
0 |
0 |
11 |
1 |
4 |
11 |
132 |
| Contributions to Federal Election Campaigns by Government Contractors |
0 |
0 |
0 |
19 |
0 |
2 |
3 |
308 |
| Do (More and Better) Drugs Keep People Out of Hospitals? |
0 |
0 |
0 |
281 |
5 |
8 |
9 |
673 |
| Does Foreign Direct Investment Transfer Technology Across Borders? |
0 |
2 |
10 |
675 |
1 |
5 |
36 |
1,843 |
| Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization |
1 |
1 |
8 |
74 |
2 |
6 |
17 |
237 |
| Energy prices and induced innovation |
0 |
0 |
0 |
58 |
1 |
2 |
2 |
116 |
| Errors of Measurement in Output Deflators |
0 |
0 |
0 |
0 |
1 |
4 |
7 |
256 |
| Estimation of the Internal Adjustment Costs Model Using Longitudinal Establishment Data |
0 |
0 |
0 |
23 |
2 |
3 |
4 |
152 |
| Has Medical Innovation Reduced Cancer Mortality? |
0 |
0 |
1 |
7 |
1 |
2 |
4 |
54 |
| Has Pharmaceutical Innovation Reduced Social Security Disability Growth? |
0 |
0 |
0 |
12 |
1 |
1 |
1 |
64 |
| Has Using Newer Drugs Reduced Admissions to Hospitals and Nursing Homes? |
0 |
0 |
1 |
23 |
1 |
2 |
5 |
105 |
| Has pharmaceutical innovation reduced the average cost of U.S. health care episodes? |
0 |
1 |
1 |
3 |
1 |
6 |
10 |
15 |
| Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country‐level data on 20 OECD countries, 1995–2003 |
0 |
0 |
0 |
26 |
0 |
1 |
5 |
276 |
| How elastic is the government's demand for weapons? |
1 |
1 |
3 |
19 |
2 |
4 |
14 |
211 |
| IMPORTATION AND INNOVATION |
0 |
0 |
0 |
28 |
3 |
5 |
5 |
345 |
| IR & D project data and theories of R & D investment |
0 |
0 |
0 |
6 |
2 |
2 |
4 |
58 |
| Industrial de-diversification and its consequences for productivity |
0 |
0 |
0 |
48 |
3 |
3 |
9 |
233 |
| Information technology and its impact on firm-level productivity: evidence from government and private data sources, 1977-1993 |
0 |
0 |
1 |
220 |
1 |
1 |
6 |
752 |
| Interindustry Technology Flows and Productivity Growth: A Re-examination |
0 |
0 |
0 |
247 |
0 |
1 |
10 |
620 |
| International R&D spillovers: A comment |
0 |
1 |
3 |
370 |
1 |
3 |
8 |
997 |
| Issues in measuring industrial R&D |
0 |
0 |
0 |
26 |
0 |
2 |
3 |
78 |
| Labour market institutions, liquidity constraints, and macroeconomic stability |
0 |
0 |
0 |
9 |
2 |
2 |
5 |
133 |
| Managerial ownership and firm performance: A re-examination using productivity measurement |
1 |
1 |
2 |
190 |
4 |
6 |
9 |
473 |
| Ownership structure and corporate performance in Japan |
0 |
1 |
2 |
124 |
3 |
4 |
11 |
466 |
| Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data |
0 |
0 |
0 |
39 |
0 |
0 |
3 |
210 |
| Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010 |
0 |
0 |
0 |
11 |
0 |
2 |
4 |
96 |
| Pharmaceutical Price Discrimination and Social Welfare |
0 |
0 |
0 |
62 |
2 |
5 |
7 |
282 |
| Pharmaceutical innovation and mortality in the United States, 1960-2000. A commentary on Schnittker and Karandinos |
0 |
0 |
1 |
25 |
0 |
1 |
2 |
82 |
| Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as 'Equipment for Your Health' |
0 |
0 |
0 |
39 |
1 |
2 |
2 |
305 |
| Productivity and Changes in Ownership of Manufactoring Plants |
0 |
1 |
2 |
109 |
0 |
2 |
4 |
400 |
| Rejoinder to comment by Maarten Vendrik |
0 |
0 |
0 |
11 |
1 |
1 |
2 |
123 |
| Sources of U.S. longevity increase, 1960-2001 |
0 |
0 |
2 |
155 |
2 |
3 |
8 |
506 |
| Spurious correlation in estimation of the health production function: A note |
0 |
0 |
0 |
58 |
2 |
3 |
5 |
391 |
| THE EFFECT OF CONTROL CHANGES ON THE PRODUCTIVITY OF U.S. MANUFACTURING PLANTS |
0 |
0 |
2 |
27 |
2 |
3 |
8 |
70 |
| THE IMPACT OF NEW DRUG LAUNCHES ON LIFE-YEARS LOST IN 2015 FROM 19 TYPES OF CANCER IN 36 COUNTRIES |
0 |
1 |
1 |
1 |
1 |
2 |
5 |
7 |
| Testing the Convergence Hypothesis |
0 |
0 |
1 |
353 |
1 |
4 |
7 |
1,331 |
| The Comparative Advantage of Educated Workers in Implementing New Technology |
0 |
0 |
2 |
809 |
2 |
8 |
23 |
3,831 |
| The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry |
0 |
1 |
1 |
32 |
3 |
5 |
9 |
290 |
| The Effect of Government Funding on Private Industrial Research and Development: A Re-assessment |
0 |
0 |
7 |
234 |
1 |
3 |
16 |
672 |
| The Effect of Ownership Changes on the Employment and Wages of Central Office and Other Personnel |
0 |
0 |
0 |
16 |
0 |
1 |
2 |
443 |
| The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996–2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files |
0 |
0 |
1 |
41 |
4 |
5 |
9 |
226 |
| The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003 |
0 |
0 |
1 |
3 |
0 |
1 |
4 |
61 |
| The Effects of Medicare on Health Care Utilization and Outcomes |
0 |
0 |
0 |
139 |
2 |
2 |
2 |
947 |
| The Health Impact of, and access to, New Drugs in Korea |
0 |
0 |
0 |
3 |
0 |
1 |
4 |
20 |
| The Impact and Organization of Publicly-Funded Research and development in the European Community |
0 |
0 |
0 |
2 |
0 |
2 |
4 |
143 |
| The Impact of Biopharmaceutical Innovation on Disability, Social Security Recipiency, and Use of Medical Care of U.S. Community Residents, 1998–2015 |
1 |
1 |
2 |
3 |
1 |
1 |
3 |
7 |
| The Impact of New Drug Launch on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries |
0 |
0 |
0 |
6 |
1 |
2 |
7 |
63 |
| The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis |
0 |
1 |
1 |
9 |
2 |
5 |
13 |
43 |
| The Impact of New Drug Launches on Longevity Growth in Nine Middle Eastern and African Countries, 2007–2015 |
0 |
0 |
0 |
15 |
3 |
8 |
12 |
79 |
| The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001 |
0 |
0 |
0 |
120 |
0 |
0 |
1 |
471 |
| The Impact of New Drugs on US Longevity and Medical Expenditure, 1990–2003: Evidence from Longitudinal, Disease-Level Data |
0 |
0 |
0 |
59 |
2 |
2 |
5 |
253 |
| The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004–2012 |
0 |
0 |
0 |
6 |
1 |
3 |
4 |
56 |
| The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010 |
0 |
0 |
0 |
27 |
0 |
3 |
5 |
93 |
| The Impact of Pharmaceutical Innovation on Premature Mortality, Cancer Mortality, and Hospitalization in Slovenia, 1997–2010 |
0 |
0 |
0 |
5 |
1 |
3 |
6 |
64 |
| The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia |
0 |
0 |
0 |
6 |
0 |
0 |
2 |
40 |
| The Impact of Public and Private Research on Premature Cancer Mortality and Hospitalization in the United States, 1999-2013 |
0 |
0 |
0 |
2 |
1 |
1 |
1 |
15 |
| The Impact of R&D Investment on Productivity--New Evidence Using Linked R&D-LRD Data |
0 |
0 |
0 |
0 |
0 |
4 |
12 |
1,059 |
| The Managerial Response to Regulation of Financial Reporting for Segments of a Business Enterprise |
0 |
0 |
0 |
1 |
11 |
12 |
12 |
352 |
| The Private R&D Investment Response to Federal Design and Technical Competitions |
0 |
0 |
3 |
199 |
3 |
6 |
16 |
730 |
| The Relationship between Federal Contract R&D and Company R&D |
0 |
0 |
0 |
9 |
13 |
37 |
54 |
757 |
| The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996–2019 |
0 |
0 |
2 |
4 |
2 |
3 |
7 |
16 |
| The benefits to society of new drugs: a survey of the econometric evidence |
0 |
0 |
0 |
77 |
1 |
3 |
3 |
405 |
| The burden of government:, Stanford: Hoover Institution Press, 1986. x + 188 pp., $23.95 |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
51 |
| The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004 |
0 |
0 |
1 |
85 |
1 |
1 |
6 |
462 |
| The effect of new drug approvals on HIV mortality in the US, 1987-1998 |
0 |
0 |
0 |
16 |
0 |
0 |
0 |
108 |
| The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010 |
0 |
0 |
0 |
5 |
2 |
4 |
5 |
60 |
| The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries |
0 |
0 |
0 |
0 |
1 |
2 |
3 |
5 |
| The effects of dynamic and static competition on prescription drug prices in Denmark, 1997–2017 |
0 |
1 |
1 |
3 |
3 |
5 |
8 |
16 |
| The effects of leveraged buyouts on productivity and related aspects of firm behavior |
0 |
2 |
9 |
595 |
7 |
15 |
53 |
1,706 |
| The impact of biomedical innovation on the disability of elderly Medicare recipients, 2013–2019 |
0 |
0 |
0 |
1 |
1 |
2 |
3 |
8 |
| The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007 |
0 |
0 |
0 |
2 |
1 |
3 |
3 |
42 |
| The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013 |
0 |
0 |
1 |
2 |
0 |
0 |
3 |
38 |
| The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009 |
0 |
0 |
0 |
34 |
2 |
6 |
9 |
138 |
| The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: evidence from longitudinal, disease-level data |
0 |
0 |
1 |
6 |
2 |
6 |
11 |
84 |
| The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011 |
0 |
0 |
0 |
8 |
0 |
1 |
4 |
79 |
| The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence |
0 |
0 |
0 |
5 |
0 |
3 |
5 |
53 |
| The impact of therapeutic procedure innovation on hospital patient longevity: Evidence from Western Australia, 2000–2007 |
0 |
0 |
0 |
5 |
2 |
4 |
7 |
136 |
| The long-run impact of new medical ideas on cancer survival and mortality |
0 |
0 |
0 |
3 |
2 |
2 |
3 |
25 |
| The quality of medical care, behavioral risk factors, and longevity growth |
0 |
0 |
0 |
32 |
0 |
1 |
2 |
247 |
| Total Journal Articles |
4 |
17 |
79 |
6,173 |
135 |
297 |
656 |
27,639 |
LogEc is hosted by the
Örebro University School of Business.